The estimated Net Worth of John Gill is at least $653 ezer dollars as of 12 August 2022. Mr. Gill owns over 2,714 units of Altimmune Inc stock worth over $19,868 and over the last 7 years he sold ALT stock worth over $141,136. In addition, he makes $492,235 as Independent Director at Altimmune Inc.
John has made over 4 trades of the Altimmune Inc stock since 2017, according to the Form 4 filled with the SEC. Most recently he sold 2,714 units of ALT stock worth $40,710 on 12 August 2022.
The largest trade he's ever made was exercising 16,850 units of Altimmune Inc stock on 24 September 2020 worth over $120,815. On average, John trades about 2,635 units every 172 days since 2017. As of 12 August 2022 he still owns at least 2,771 units of Altimmune Inc stock.
You can see the complete history of Mr. Gill stock trades at the bottom of the page.
John M. Gill serves as Independent Director of the Company. Mr. Gill has served on our Board since 2004. From 2003 to 2013, Mr. Gill served as the President, Chief Executive Officer, co-founder and a Director of TetraLogic Pharmaceuticals Corporation, a public biopharmaceutical company. Mr. Gill has previously held positions at 3-Dimensional Pharmaceuticals and SmithKline Beecham. After serving in the United States Marine Corps, Mr. Gill earned a B.A. from Rutgers University. Mr. Gill was chosen to serve as a director of Altimmune because of his executive and board experience in the pharmaceutical industry and his substantial financial knowledge and expertise.
As the Independent Director of Altimmune Inc, the total compensation of John Gill at Altimmune Inc is $492,235. There are 5 executives at Altimmune Inc getting paid more, with Dr. Vipin K. Garg Ph.D. having the highest compensation of $897,696.
John Gill is 68, he's been the Independent Director of Altimmune Inc since 2017. There are 3 older and 9 younger executives at Altimmune Inc. The oldest executive at Altimmune Inc is David Drutz, 81, who is the Independent Director.
John's mailing address filed with the SEC is C/O ALTIMMUNE, INC.,, 910 CLOPPER ROAD, SUITE 201S, GAITHERSBURG, MD, 20878.
Over the last 7 years, insiders at Altimmune Inc have traded over $2,557,810 worth of Altimmune Inc stock and bought 3,362,060 units worth $23,898,779 . The most active insiders traders include Bioventures Ltd Novartis Ag..., Healthcare Capital Partners... és Mitchel Sayare. On average, Altimmune Inc executives and independent directors trade stock every 35 days with the average trade being worth of $432,889. The most recent stock trade was executed by David Drutz on 19 August 2024, trading 41,750 units of ALT stock currently worth $106,463.
altimmune, inc. is a clinical stage biotechnology company developing next-generation immunotherapeutics and vaccines to address significant public health and biodefense needs. by leveraging specific attributes of its two independent and complementary platform technologies, altimmune can rapidly design product candidates against a wide range of disease targets, including respiratory diseases, chronic infections, and cancer. our densigen™ t-cell platform technology is uniquely suited to direct the immune response against traditionally difficult disease targets, including chronic infections and cancer, by directing an individual’s immune system against multiple target antigens instead of just one. altimmune’s respirvec™ platform utilizes convenient needle-free intranasal delivery to achieve broad immunity against disease pathogens more rapidly than conventional vaccines. vaxin’s product candidates are easily manufactured, highly stable, and provide a safe, effective alternative to current
Altimmune Inc executives and other stock owners filed with the SEC include: